



(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 31/5375 (2006.01)
A61K 31/444 (2006.01) A61K 31/555 (2006.01)
A61K 31/337 (2006.01) A61K 31/7068 (2006.01)
A61K 31/4745 (2006.01) A61P 35/00 (2006.01)
A61K 31/501 (2006.01) A61K 31/5377 (2006.01)
A61K 31/513 (2006.01)

(21) International Application Number:

PCT/US2023/017805

(22) International Filing Date:

07 April 2023 (07.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/329,010 08 April 2022 (08.04.2022) US
63/345,736 25 May 2022 (25.05.2022) US

(71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: BELMONTES, Brian; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks,

CA 91320-1799 (US). CHAN, Edward, Lau Yue; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). HUGHES, Paul; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). SLEMMONS, Katherine; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). SUN, Jan; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: BRASHEAR, Jeanne, M.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: CANCER TREATMENTS USING MTA-COOPERATIVE PRMT5 INHIBITORS




Figure 1

(57) Abstract: Described herein are methods of treating cancer in a patient comprising administering a PRMT5 inhibitor. Also provided are methods of treating cancer in a patient comprising administering a PRMT5 inhibitor and a standard of care therapy.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))